CM338

BIOLOGICAL2 trials

Sponsors

Keymed Biosciences Co.Ltd

Conditions

HealthyIgA Nephropathy

Phase 1

Single Ascending Dose Study of CM338 in Healthy Volunteers

CompletedNCT05186285

Keymed Biosciences Co.LtdHealthy

Start: 2021-12-11End: 2022-07-27Updated: 2024-11-08

Phase 2

Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

RecruitingNCT05775042

Keymed Biosciences Co.LtdIgA Nephropathy

Start: 2023-05-08End: 2027-06-30Target: 70Updated: 2024-10-15